Building a leading microbiome

company in oncology

We are a clinical-stage microbiome therapeutics company
aiming to improve survival in cancer.

Our strengths

A full ecosystem approach

Oncology focused

AI-Powered Drug Development

cGMP Versatile Manufacturing Capacities

Latest News

December 2, 2022

MedNous – FDA approves first faecal microbiota product

December 2, 2022

Labiotech – FDA’s approval of first fecal microbiota product, Rebyota, hailed an ‘enormous step forward’ for the field

November 29, 2022

November 29, 2022: MaaT Pharma To Webcast Investor Meeting in Conjunction with ASH 2022 Conference

Like what you see? See more posts

Join the MaaT Pharma adventure!

Bring your talents, your passion and join an inclusive, creative, and multidisciplinary team. We aim to leverage the potential of microbiome to improve the treatment of patients with cancer.

Learn more about our values, our environment and see what we have to offer to you!